Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
CELC Stock Chart & Stats
$98.48
-$0.35(-2.63%)
At close: 4:00 PM EST
$98.48
-$0.35(-2.63%)
Day’s Range― - ―
52-Week Range$7.58 - $103.06
Previous CloseN/A
Volume14.25K
Average Volume (3M)962.63K
Market Cap
$4.51B
Enterprise Value$2.22B
Total Cash (Recent Filing)$454.98M
Total Debt (Recent Filing)$320.35M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 19, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding46,271,260
10 Day Avg. Volume846,838
30 Day Avg. Volume962,630
Financial Highlights & Ratios
PEG Ratio-0.89
Price to Book (P/B)4.47
Price to Sales (P/S)0.00
P/FCF Ratio-6.17
Enterprise Value/Market Cap0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-29.45K
Enterprise Value/Ebitda-16.35
Forecast
1Y Price Target
$98.43Price Target Upside-0.05% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessCelcuity's Phase 3 VIKTORIA-1 trial showed detailed results that exceeded expectations with a favorable overall survival rate for the PIK3CA WT cohort.
Financial StrengthCELC has $455M in cash and seems well capitalized ahead of a commercial launch for geda.
Regulatory ApprovalThe FDA has agreed to accept the NDA application for approval of gedatolisib as a therapy for advanced breast cancer with wild-type PIK3CA.
Bears Say
Competitive RisksThe company could be tasked to compete against some of the large cap pharma companies with proven commercial infrastructure in breast cancer.
Market SkepticismShort interest in Celcuity's stock is relatively high at 28.2% of the float, indicating potential market skepticism.
Market Valuation ConcernsCELC appears priced for perfection with more downside risk than upside.
Celcuity News
CELC FAQ
What was Celcuity’s price range in the past 12 months?
Celcuity lowest stock price was $7.58 and its highest was $103.06 in the past 12 months.
What is Celcuity’s market cap?
Celcuity’s market cap is $4.51B.
When is Celcuity’s upcoming earnings report date?
Celcuity’s upcoming earnings report date is Mar 19, 2026 which is in 105 days.
How were Celcuity’s earnings last quarter?
Celcuity released its earnings results on Nov 12, 2025. The company reported -$0.92 earnings per share for the quarter, beating the consensus estimate of -$1.019 by $0.099.
Is Celcuity overvalued?
According to Wall Street analysts Celcuity’s price is currently Overvalued.
Does Celcuity pay dividends?
Celcuity does not currently pay dividends.
What is Celcuity’s EPS estimate?
Celcuity’s EPS estimate is -1.05.
How many shares outstanding does Celcuity have?
Celcuity has 46,271,260 shares outstanding.
What happened to Celcuity’s price movement after its last earnings report?
Celcuity reported an EPS of -$0.92 in its last earnings report, beating expectations of -$1.019. Following the earnings report the stock price went up 0.998%.
Which hedge fund is a major shareholder of Celcuity?
Currently, no hedge funds are holding shares in CELC
Celcuity Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.43 (-0.05% Downside)
$98.43 (-0.05% Downside)
Blogger Sentiment
Bullish
CELC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
669.41%
12-Months-Change
Fundamentals
Return on Equity
-122.04%
Trailing 12-Months
Asset Growth
74.34%
Trailing 12-Months
Company Description
Celcuity
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
CELC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong position for Celcuity, with significant clinical and regulatory progress, a solid financial foundation, and promising market potential. However, the increased financial loss and regulatory uncertainties present challenges that need to be addressed.View all CELC earnings summariesCELC Stock 12 Month Forecast
Average Price Target
$98.43
▼(-0.05% Downside)
Technical Analysis
Cidara Therapeutics
―
IDEAYA Biosciences
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Apogee Therapeutics
―
Ownership Overview
25.63% Insiders
10.11% Mutual Funds
51.61% Other Institutional Investors
4.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---